Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term Outcomes

Koen van Besien, Jeanette Carreras, Philip Jay Bierman, Brent R. Logan, Arturo Molina, Roberta King, Gene Nelson, Joseph W. Fay, Richard E. Champlin, Hillard M. Lazarus, Julie Marie Vose, Parameswaran N. Hari

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma (NHL) facilitated by the Center for International Blood and Marrow Transplant Research/National Marrow Donor Program (CIBMTR/NMDP) between 1991 and 2004. All patients received myeloablative conditioning regimens. The median follow-up of survivors is 5 years. Seventy-three (26%) patients are alive. The day 100 probability of death from all causes is estimated at 39%. The cumulative incidence of developing grade III-IV acute graft-versus-host disease (aGVHD) at day 100 is 25%. The estimated 5-year survival and failure free survival are 24% (95% confidence interval [CI]: 19-30) and 22% (95% CI: 17-28), respectively. Factors adversely associated with overall survival (OS) included increasing age, decreased performance status, and refractory disease. Follicular lymphoma (FL) and peripheral T cell lymphoma had improved survival compared to aggressive B cell lymphomas. Factors adversely associated with progression-free survival (PFS) included performance status, histology, and disease status at transplant. Long-term failure-free survival is possible following unrelated donor transplantation for NHL, although early mortality was high in this large cohort.

Original languageEnglish (US)
Pages (from-to)554-563
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Volume15
Issue number5
DOIs
StatePublished - May 1 2009

Fingerprint

Unrelated Donors
Cell Transplantation
Non-Hodgkin's Lymphoma
Survival
Bone Marrow
Confidence Intervals
Peripheral T-Cell Lymphoma
Transplants
Follicular Lymphoma
B-Cell Lymphoma
Graft vs Host Disease
Disease-Free Survival
Survivors
Cause of Death
Histology
Transplantation
Tissue Donors
Mortality
Incidence
Research

Keywords

  • Lymphoma
  • Myeloablative
  • Unrelated donor

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma : Long-Term Outcomes. / van Besien, Koen; Carreras, Jeanette; Bierman, Philip Jay; Logan, Brent R.; Molina, Arturo; King, Roberta; Nelson, Gene; Fay, Joseph W.; Champlin, Richard E.; Lazarus, Hillard M.; Vose, Julie Marie; Hari, Parameswaran N.

In: Biology of Blood and Marrow Transplantation, Vol. 15, No. 5, 01.05.2009, p. 554-563.

Research output: Contribution to journalArticle

van Besien, K, Carreras, J, Bierman, PJ, Logan, BR, Molina, A, King, R, Nelson, G, Fay, JW, Champlin, RE, Lazarus, HM, Vose, JM & Hari, PN 2009, 'Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term Outcomes', Biology of Blood and Marrow Transplantation, vol. 15, no. 5, pp. 554-563. https://doi.org/10.1016/j.bbmt.2009.01.012
van Besien, Koen ; Carreras, Jeanette ; Bierman, Philip Jay ; Logan, Brent R. ; Molina, Arturo ; King, Roberta ; Nelson, Gene ; Fay, Joseph W. ; Champlin, Richard E. ; Lazarus, Hillard M. ; Vose, Julie Marie ; Hari, Parameswaran N. / Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma : Long-Term Outcomes. In: Biology of Blood and Marrow Transplantation. 2009 ; Vol. 15, No. 5. pp. 554-563.
@article{5ae7f230466b443abda49747a7288a57,
title = "Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term Outcomes",
abstract = "We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma (NHL) facilitated by the Center for International Blood and Marrow Transplant Research/National Marrow Donor Program (CIBMTR/NMDP) between 1991 and 2004. All patients received myeloablative conditioning regimens. The median follow-up of survivors is 5 years. Seventy-three (26{\%}) patients are alive. The day 100 probability of death from all causes is estimated at 39{\%}. The cumulative incidence of developing grade III-IV acute graft-versus-host disease (aGVHD) at day 100 is 25{\%}. The estimated 5-year survival and failure free survival are 24{\%} (95{\%} confidence interval [CI]: 19-30) and 22{\%} (95{\%} CI: 17-28), respectively. Factors adversely associated with overall survival (OS) included increasing age, decreased performance status, and refractory disease. Follicular lymphoma (FL) and peripheral T cell lymphoma had improved survival compared to aggressive B cell lymphomas. Factors adversely associated with progression-free survival (PFS) included performance status, histology, and disease status at transplant. Long-term failure-free survival is possible following unrelated donor transplantation for NHL, although early mortality was high in this large cohort.",
keywords = "Lymphoma, Myeloablative, Unrelated donor",
author = "{van Besien}, Koen and Jeanette Carreras and Bierman, {Philip Jay} and Logan, {Brent R.} and Arturo Molina and Roberta King and Gene Nelson and Fay, {Joseph W.} and Champlin, {Richard E.} and Lazarus, {Hillard M.} and Vose, {Julie Marie} and Hari, {Parameswaran N.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1016/j.bbmt.2009.01.012",
language = "English (US)",
volume = "15",
pages = "554--563",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma

T2 - Long-Term Outcomes

AU - van Besien, Koen

AU - Carreras, Jeanette

AU - Bierman, Philip Jay

AU - Logan, Brent R.

AU - Molina, Arturo

AU - King, Roberta

AU - Nelson, Gene

AU - Fay, Joseph W.

AU - Champlin, Richard E.

AU - Lazarus, Hillard M.

AU - Vose, Julie Marie

AU - Hari, Parameswaran N.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma (NHL) facilitated by the Center for International Blood and Marrow Transplant Research/National Marrow Donor Program (CIBMTR/NMDP) between 1991 and 2004. All patients received myeloablative conditioning regimens. The median follow-up of survivors is 5 years. Seventy-three (26%) patients are alive. The day 100 probability of death from all causes is estimated at 39%. The cumulative incidence of developing grade III-IV acute graft-versus-host disease (aGVHD) at day 100 is 25%. The estimated 5-year survival and failure free survival are 24% (95% confidence interval [CI]: 19-30) and 22% (95% CI: 17-28), respectively. Factors adversely associated with overall survival (OS) included increasing age, decreased performance status, and refractory disease. Follicular lymphoma (FL) and peripheral T cell lymphoma had improved survival compared to aggressive B cell lymphomas. Factors adversely associated with progression-free survival (PFS) included performance status, histology, and disease status at transplant. Long-term failure-free survival is possible following unrelated donor transplantation for NHL, although early mortality was high in this large cohort.

AB - We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma (NHL) facilitated by the Center for International Blood and Marrow Transplant Research/National Marrow Donor Program (CIBMTR/NMDP) between 1991 and 2004. All patients received myeloablative conditioning regimens. The median follow-up of survivors is 5 years. Seventy-three (26%) patients are alive. The day 100 probability of death from all causes is estimated at 39%. The cumulative incidence of developing grade III-IV acute graft-versus-host disease (aGVHD) at day 100 is 25%. The estimated 5-year survival and failure free survival are 24% (95% confidence interval [CI]: 19-30) and 22% (95% CI: 17-28), respectively. Factors adversely associated with overall survival (OS) included increasing age, decreased performance status, and refractory disease. Follicular lymphoma (FL) and peripheral T cell lymphoma had improved survival compared to aggressive B cell lymphomas. Factors adversely associated with progression-free survival (PFS) included performance status, histology, and disease status at transplant. Long-term failure-free survival is possible following unrelated donor transplantation for NHL, although early mortality was high in this large cohort.

KW - Lymphoma

KW - Myeloablative

KW - Unrelated donor

UR - http://www.scopus.com/inward/record.url?scp=63749130619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63749130619&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.01.012

DO - 10.1016/j.bbmt.2009.01.012

M3 - Article

C2 - 19361747

AN - SCOPUS:63749130619

VL - 15

SP - 554

EP - 563

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 5

ER -